Skip to content

Clinical Study on Oral Andrographolide to Promote Stem Cell Mobilization in Elderly Donors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Study on Oral Andrographolide to Promote Stem Cell Mobilization in Elderly Donors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125026
Enrollment
Unknown
Registered
2026-05-20
Start date
2026-05-20
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic stem cell transplantation

Interventions

Experimental group:Oral Andrographolide

Sponsors

The Second Affiliated Hospital of the Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age between 50 and 70 years, gender not specified; 2.Planned as a healthy donor for allogeneic hematopoietic stem cell transplantation; 3.Qualified after comprehensive medical examination, with no contraindications for hematopoietic stem cell collection;

Exclusion criteria

Exclusion criteria: 1.Pregnant or breastfeeding women; 2.There are serious organic diseases or dysfunctions of the heart, liver, kidneys, or brain; 3.Allergic to andrographolide or the excipients in its preparations; 4.Currently participating in other interventional clinical studies that may affect the results of this study;

Design outcomes

Primary

MeasureTime frame
Comprehensive Assessment of the Safety of Oral Andro in Elderly Donors;

Secondary

MeasureTime frame
Functional indicators of donor HSC;Efficiency index of donor mobilization;Receiver exploratory indicators;

Countries

China

Contacts

Public ContactZhang Xi

The Second Affiliated Hospital of the Army Medical University

zhangxxi@sina.com+86 23 68763198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026